Completed PHASE3 INTERVENTIONAL 3-arm NCT00007683

Warfarin and Antiplatelet Therapy in Chronic Heart Failure

CSP #442 - Warfarin and Antiplatelet Therapy Study in Patients With Congestive Heart Failure (WATCH)

Sponsor: Bristol-Myers Squibb

Interventions Aspirin Clopidogrel 75 Warfarin titrated to an INR of 2.5-3.0

Updated 7 times since 2017 Last updated: Jun 14, 2011 Started: Oct 31, 1998 Primary completion: Jul 31, 2003 Completion: Dec 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Heart Failure and is currently completed. Bristol-Myers Squibb leads this study, which shows 7 recorded versions since 1998 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Aug 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Jun 2018 — Aug 2018 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Oct 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bristol-Myers Squibb
Sanofi-Synthelabo
US Department of Veterans Affairs

Data source: VA Office of Research and Development

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ajax, Canada , Albany, United States , Ann Arbor, United States , Atlantis, United States , Augusta, United States , Barnsley, United Kingdom , Bay Pines, United States , Bedford, United States , Belfast, United Kingdom , Biloxi, United States and 119 more locations